|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||221.30 g/mol g·mol−1|
|3D model (JSmol)|
Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed. Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery. Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|